CELLULAR AND MOLECULAR LIFE SCIENCES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2025-12-13 ms6000000399391423 来自北京

审稿速度:3.0
偏重的研究方向：分子生物学
经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了

76 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2025-01-06 ms6000000136446040 来自上海

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：2024.06.05 submitted to journal
2024.06.12 under review
2024.06.28 under review
2024.07.15 under review
2024.07.25 major revision (two reviewers)
2024.10.30 Revision Submitted to Journal
2024.12.02 minor revision
2024.12.20 Revision Submitted to Journal
2025.01.04 accept

149 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2023-11-09 默默0606 来自北京

偏重的研究方向：细胞生物学
经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……

246 11 举报

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2023-03-06 ms4000002086735612 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：免疫;转录调控;表观
经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了
20221123 with editor
1127 Under Review
1128 Under Review
1201 Under Review
1207 Under Review
1222 Required Reviews Completed
1226 Major Revision
20230206 Revision Submittedd to Journal
20230207 With Editor
20230208 Under Review
20230221 Required Reviews Completed
20230303 Accept

195 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2024-08-07 于陌上来自吉林省

审稿速度:12.0 | 投稿命中率:50.0
偏重的研究方向：分子生物学
经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept

194 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2023-12-28 ms5000000204318340 来自山东省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：2023.9.26 Submitted to journal
2023.9.30 With Editor
2023.10.3 Under review
2023.11.3 Required reviews completed
2023.11.13 Major revision
2023.12.25 Revision submitted to journal
2023.12.26 With Editor
2023.12.26 Under review
2023.12.27 Required reviews completed
2023.12.27 Accept

247 6 举报

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2023-10-16 科研小麻瓜来自广东省

这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？

403 20 举报

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2021-11-16 山蛙

审稿速度:2.0 | 投稿命中率:25.0
经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。

323 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2022-08-09 ms2000000705029865

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：分子生物学;肿瘤;分子机制
经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好

239 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2293105, encodeId=bcea229310543, content=审稿速度:3.0 偏重的研究方向：分子生物学 经验分享：我的卡在了一审 under review 两个月了，正常吗？需要催稿吗？急着毕业，太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65da9104740, createdName=ms6000000399391423, createdTime=Sat Dec 13 15:18:57 CST 2025, time=2025-12-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246784, encodeId=9ac12246e844b, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：2024.06.05 submitted to journal 2024.06.12 under review 2024.06.28 under review 2024.07.15 under review 2024.07.25 major revision (two reviewers) 2024.10.30 Revision Submitted to Journal 2024.12.02 minor revision 2024.12.20 Revision Submitted to Journal 2025.01.04 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=109a8327611, createdName=ms6000000136446040, createdTime=Mon Jan 06 09:25:38 CST 2025, time=2025-01-06, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2167682, encodeId=2f57216e6826a, content=偏重的研究方向：细胞生物学 经验分享：这个杂志一开始看评论很快，大概七月底投得，with editor三周，可是under review将近三个月了还是under review，这是怎么了，急啊。不知道还要多久……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/hp5icltiaJTLo0VTcHpibDaN1myRIOsia0uClo6Z2CrEt7ZM0dMXHLPwEa6Q1Hc59vJyaqTQIX38UrAfrkcKPVU5gQ/132, createdBy=84602344041, createdName=默默0606, createdTime=Thu Nov 09 21:23:20 CST 2023, time=2023-11-09, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2117900, encodeId=808d211e90005, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫;转录调控;表观 经验分享：感觉编辑处理的很快，Under Review这么快我都有点不相信，投稿时间过程分享给大家。3个审稿人问的问题很仔细，有些结论我写的有些唐突了，审稿人还帮我提出了一些结论分享给我，学习到了很多。其中一个审稿人必须让我补一个实验，有点强人所难，还是没有补，好说歹说给他分析了一些公共数据，还好审稿人心软，感谢了 20221123 with editor 1127 Under Review 1128 Under Review 1201 Under Review 1207 Under Review 1222 Required Reviews Completed 1226 Major Revision 20230206 Revision Submittedd to Journal 20230207 With Editor 20230208 Under Review 20230221 Required Reviews Completed 20230303 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=550f8099523, createdName=ms4000002086735612, createdTime=Mon Mar 06 11:04:26 CST 2023, time=2023-03-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2218885, encodeId=18f3221888523, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学 经验分享：2023.9.1 submitted to journal 2023.9.1 with editor 2023.9.19 with editor 2023.10.26 Under Review 2023.11.17 Under Review 2023.11.30 Under Review 2023.12.17 Under Review 2024.1.7 Under Review 2024.1.9 Under Review 2024.2.6 Under Review 2024.3.3 Under Review 2024.3.22 Required Reviews completed 2024.3.24 Major Revision (Date Revision Due 2024.5.5) 2024.5.5 Revision Submitted to Journal 2024.5.6 with editor 2024.5.20 Under Review 2024.6.6 major Revision (Date Revision Due 2024.7.17) 2024.7.17 Revision Submitted to Journal 2024.7.18 with editor 2024.7.22 Under Review 2024.8.6 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bb81967620, createdName=于陌上, createdTime=Wed Aug 07 05:56:17 CST 2024, time=2024-08-07, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2177695, encodeId=422721e76958a, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：2023.9.26 Submitted to journal 2023.9.30 With Editor 2023.10.3 Under review 2023.11.3 Required reviews completed 2023.11.13 Major revision 2023.12.25 Revision submitted to journal 2023.12.26 With Editor 2023.12.26 Under review 2023.12.27 Required reviews completed 2023.12.27 Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09736486374, createdName=ms5000000204318340, createdTime=Thu Dec 28 09:39:53 CST 2023, time=2023-12-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2163073, encodeId=7d5621630e315, content=这个杂志是怎么回事，投稿近一个月还是with editor，转OA了变慢了吗？我想三月份见刊，还有没有戏，等多久催编辑部呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=403, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/d7902bcf52f94c5190172309606f3858/06092b9280764246ad42c419b945d52c.jpg, createdBy=abac5169286, createdName=科研小麻瓜, createdTime=Mon Oct 16 14:46:32 CST 2023, time=2023-10-16, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1070677, encodeId=a56510e067742, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：CMLS是欧洲老牌期刊，对研究型论文要求很高，缺乏创新和深度的文章一般连外审的机会都没有！至于综述，通讯作者的研究履历是一个重要机会。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=323, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Tue Nov 16 09:33:51 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237659, encodeId=b24e123e6590b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;肿瘤;分子机制 经验分享：欧洲老牌杂志，三天内with editor, 十天内Under review，一个月内Minor revision,要求文章创新性比较高，数据全面且研究深入，审稿人意见比较专业，提了许多比较细的问题，总的来说还是比较难投，感觉对国人还算友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67145690565, createdName=ms2000000705029865, createdTime=Tue Aug 09 17:53:23 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2189423, encodeId=3331218942342, content=no, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e838161588, createdName=ms4000000389646164, createdTime=Mon Feb 26 11:31:22 CST 2024, time=2024-02-26, status=1, ipAttribution=浙江省)]

2024-02-26 ms4000000389646164 来自浙江省

no

1 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务